Last reviewed · How we verify
NCT02978391
UI-EWD for Endoscopic Hemostasis of Bleeding Peptic Ulcers and Bleeding After EMR/ESD
NA trial testing UI-EWD Hemostatic system in Upper Gastrointestinal Bleeding in 76 participants. Completed in 18 September 2017.
30 November 2016
Quick facts
| Lead sponsor | Next Biomedical Co., Ltd. |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 76 |
| Start date | 23 May 2016 |
| Primary completion | 30 November 2016 |
| Estimated completion | 18 September 2017 |
| Sites | 2 locations across South Korea |
Drugs / interventions tested
- UI-EWD Hemostatic system
- epinephrine endoscopic injection (conventional therapy) — full drug profile →
Conditions studied
- Upper Gastrointestinal Bleeding — all drugs for Upper Gastrointestinal Bleeding →
Sponsor
Next Biomedical Co., Ltd. — full company profile →
Who can join
20 and older, any sex, with Upper Gastrointestinal Bleeding. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
UI-EWD (NextBiomedical Co, Incheon, South Korea), a new hemostatic powder for endoscopic treatment of high-risk bleeding peptic ulcers and bleeding after ESD/EMR.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT02978391
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Upper Gastrointestinal Bleeding
Currently open trials in the same condition.
- NCT04902248 — OTSC vs. Angiographic Embolization in Patients With Refractory Non-variceal Upper Gastrointestinal Bleeding · NA · recruiting
Other Next Biomedical Co., Ltd. trials
Trials by the same sponsor.
- NCT06207851 — Transcatheter Arterial Micro-Embolization (TAME) Using Nexsphere-F in Patients With Chronic Pain in Elbow or Wrist · NA · recruiting
- NCT06229080 — Short-term Embolization Using Gelatin Particles for FloW ModulAtion During Y90 Radioembolization · NA · completed
- NCT05884931 — Effectiveness and Safety of Nexpowder as an Endoscopic Hemostatic Treatment · NA · completed
- NCT05072041 — Safety and Efficacy of Degradable Microsphere in Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma · NA · recruiting
- NCT05086770 — Comparison of Pain After Uterine Artery Embolization Using Gelatin Microsphere or Tris-acryl Gelatin Microsphere · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02978391 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Next Biomedical Co., Ltd.
- Last refreshed: 8 April 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02978391.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing